



EOS imaging Installs System at Clinique Arago, Top-Ranking Paris Joint Surgery Center

Paris, Dec. 09, 2014 - EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer in 2D/3D orthopedic medical imaging, announced today the installation of an EOS imaging system in the number-one ranked hip and knee prosthesis clinic in France, Clinique Arago.

Founded in 1984, Clinique Arago is a specialized orthopedic surgery center that performs approximately 2,600 orthopedic procedures every year, out of which approximately 1000 hip arthroplasties and 500 knee arthroplasties. Clinique Arago has been over the last decade consistently amongst the three top public or private healthcare centers for knee and hip prosthetic surgery in the various French ranking systems. EOS has been installed in the Arago's recently opened second building.

"We pride ourselves in having a comprehensive suite of orthopedic treatments, and the addition of EOS will be incredibly useful across our spectrum of treatment options," said the radiologists at Clinique Arago. *"The 2D and 3D images obtained from the EOS system and the associated planning software hipEOS will take a lot of the guesswork out of prosthesis sizing and should allow our surgeons to more effectively visualize, plan, and more efficiently perform these replacements."*

Marie Meynadier, CEO of EOS imaging, said, *"The Clinique Arago is one of the premier destinations for lower limb joint surgery in France, and EOS imaging is proud to be included in the treatment landscape of such a prestigious center. Adoption by Clinique Arago reflects the Company's growing offering and value in joint surgery, which was recently exemplified by the launch of our hipEOS planning software for hip arthroplasty."*

The EOS® system provides stereoradiographic full-body images of patients in a natural functional position in both 2D and 3D with 50% to 85% less dose than digital radiology and 95% less dose than basic CT scans, in accordance with the ALARA (As Low As Reasonably Achievable) principle of radiation reduction, as well as associated software solutions.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit <http://www.eos-imaging.com/>.

EOS imaging has been chosen to be included in the new EnterNext® PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

About EOS imaging:

EOS imaging designs, develops, and markets EOS® and associated solutions, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market in 34 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2013 the Group posted 2013 consolidated revenue of €15.2 million and employed 106 people including an R&D team of 38 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.



EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI



Contacts:

Anne Renevot

CFO

Ph: +33 (0)1 55 25 61 24

investors@eos-imaging.com

NewCap

Financial communication and investor relations

Sophie Boulila / Pierre Laurent

Ph: +33 (0)1 44 71 94 91 - eosimaging@newcap.fr

The Ruth Group (US)

Press relations / Calvin Allen

Ph: 646-536-7002

callen@theruthgroup.com